Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor

This study has been completed.
Information provided by (Responsible Party):
Ashley Shoemaker, Vanderbilt University Identifier:
First received: October 20, 2011
Last updated: August 15, 2016
Last verified: August 2016
The purpose of this study is to determine whether exenatide can cause weight loss in patients with a history of craniopharyngioma or other brain lesion.

Condition Intervention Phase
Drug: Exenatide
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of Exenatide on Body Weight in Patients With Hypothalamic Obesity

Resource links provided by NLM:

Further study details as provided by Vanderbilt University:

Primary Outcome Measures:
  • Body Weight (kg) [ Time Frame: baseline, 50 weeks ] [ Designated as safety issue: No ]
    Change in body weight from baseline to end of study

Secondary Outcome Measures:
  • Resting Energy Expenditure (Kcals Per Day) [ Time Frame: baseline, 50 weeks ] [ Designated as safety issue: No ]
    Change in resting energy expenditure from baseline to 50 weeks

  • Visual Analogue Scales for Post-meal Satiety [ Time Frame: baseline, 50 weeks ] [ Designated as safety issue: No ]
    Change in visual analogue scales scores from baseline to 50 weeks. Higher score indicates greater satiety (minimum 0, maximum 100).

  • Insulin Secretion (Area Under the Curve) [ Time Frame: baseline, 50 weeks ] [ Designated as safety issue: No ]
    Change in insulin secretion from baseline

  • Gastric Emptying Rate (13C-octanoic Acid Isotope Excretion Half Life) [ Time Frame: baseline, 50 weeks ] [ Designated as safety issue: No ]
    Change in the isotope excretion half life during a gastric emptying test at baseline and at 50 weeks

Enrollment: 10
Study Start Date: June 2012
Study Completion Date: March 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Exenatide
All patients received exenatide 10mcg BID x 50 weeks
Drug: Exenatide
Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
Other Name: Byetta

Detailed Description:

Hypothalamic obesity occurs in up to 60% of patients with tumors in the hypothalamic region, most commonly craniopharyngiomas. Hypothalamic dysfunction can be due to tumor infiltration and as a consequence of surgery or radiation therapy. Survivors who develop obesity have greater morbidity and mortality than normal weight survivors. Prevention and treatment of obesity in this population is vital in order to decrease the morbidity and mortality from diabetes, stroke and myocardial infarction.

Exenatide (Byetta®) is a GLP-1 homologue that was FDA approved for treatment of type 2 diabetes in 2005. It also decreases the rate of gastric emptying and increases satiety and has been shown to cause weight loss in some people. Exenatide may improve insulin sensitivity and satiety in patients with hypothalamic obesity but without the risks of bariatric surgery. The investigators hypothesize that treatment with exenatide will lead to weight loss in patients with hypothalamic obesity.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age 18 to 40 years old
  • History of craniopharyngioma or other lesion in the hypothalamic region
  • Greater than 6 months post-treatment, including chemotherapy, surgery or radiation
  • BMI >30 mg/m2
  • Females must be post-menopausal, surgically sterile or using effective birth control for at least 12 weeks

Exclusion Criteria:

  • HgbA1C >7%
  • Use of diabetes medications other than metformin in the past 12 weeks, including exenatide
  • Use of weight loss drugs or initiation of a weight loss program in past 3 months
  • Impaired renal function or history of kidney transplant
  • History of gall stones (unless s/p cholecystectomy), pancreatitis or alcoholism
  • Personal or family history of medullary carcinoma of the thyroid or MEN type 2
  • History of gastroparesis or other gastric motility problems as exenatide decreases gastric motility
  • History of allergic reaction to exenatide or other medication components
  • Other significant comorbidities other than pituitary deficiencies
  • Currently prescribed warfarin (exenatide may alter warfarin metabolism)
  • Pregnant or lactating females
  • History of severe hypoglycemia (BG <60 and requiring assistance from another person)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01484873

United States, Tennessee
Vanderbilt University
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Vanderbilt University
Principal Investigator: Ashley Shoemaker, M.D. Vanderbilt University
  More Information

Additional Information:
Responsible Party: Ashley Shoemaker, Clinical Fellow, Vanderbilt University Identifier: NCT01484873     History of Changes
Other Study ID Numbers: 111185 
Study First Received: October 20, 2011
Results First Received: February 9, 2016
Last Updated: August 15, 2016
Health Authority: United States: Food and Drug Administration
Individual Participant Data  
Plan to Share IPD: No

Keywords provided by Vanderbilt University:
Hypothalamic Obesity

Additional relevant MeSH terms:
Nutrition Disorders
Body Weight
Signs and Symptoms
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Bone Neoplasms
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on October 21, 2016